Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2024
09 août 2024 02h30 HE
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 9 August 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second...
Nxera Pharma Webinar Presentation for Q2 FY2024 Financial Results
09 juil. 2024 07h14 HE
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 9 July 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for the 6 months ended 30 June 2024 on...
Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone
26 juin 2024 19h05 HE
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 27 June 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565), announces that it has reached an important R&D milestone under its multi-target discovery collaboration...
Nxera Pharma Publishes its Annual and ESG Reports for the Year ended 31 December 2023
18 juin 2024 03h55 HE
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 18 June 2024 – Nxera Pharma (“Nxera” or “the Company”; TSE 4565), today announces the publication of its Annual Report and its Environment, Social & Governance...
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals
30 mai 2024 02h35 HE
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 30 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) today announced that it expects to receive $4.6 million in milestone payments from Centessa...
Nxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area
30 mai 2024 02h30 HE
|
Nxera Pharma
Expansion of existing partnership will utilize novel insights into causal biology within auto-immune disorders to identify novel targets for drug discovery Tokyo, Japan, Oxford and Cambridge,...
Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
09 mai 2024 02h35 HE
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 9 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) notes that its partner Neurocrine Biosciences Inc. (“Neurocrine”; Nasdaq: NBIX), a leading...
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024
09 mai 2024 02h30 HE
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 9 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first...
Nxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Previous Years’ RSU Plan
17 avr. 2024 03h09 HE
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 17 April 2024 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that it has decided to issue new...
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
16 avr. 2024 02h30 HE
|
Nxera Pharma
NBI-1117568 is an oral, selective muscarinic M4 receptor agonist advancing through Phase 2 clinical development under a multi-program collaboration with Neurocrine BiosciencesSuccessful completion of...